Why Argenx’s broader Vyvgart label changes the treatment equation in generalized myasthenia gravis
Vyvgart now covers all adult gMG serotypes. Argenx gains a wider label, but payers and real-world durability remain the next test.
Viridian Therapeutics financing puts thyroid eye disease expansion strategy in sharper focus
Viridian has TED trial wins, but market entry needs capital. See why its $350m raise matters before commercialization.